1. Introduction {#sec1-nutrients-09-01223}
===============

Endometrial cancer is the third most common female cancer, after breast cancer and cervical cancer: in 2012, worldwide, there were over 1.2 million women with a diagnosis of endometrial cancer made in the previous 5 years. Similarly, in Europe there were 370,000 women with the same diagnosis \[[@B1-nutrients-09-01223]\]. The burden of non-communicable diseases, including cancers, has been associated with dietary habits, such as the consumption of fibers, sugar, saturated fatty acids, and trans fatty acids \[[@B2-nutrients-09-01223],[@B3-nutrients-09-01223],[@B4-nutrients-09-01223]\]. Among others, coffee consumption has also been shown to potentially affect human health \[[@B5-nutrients-09-01223]\]. Moderate coffee consumption has been suggested to improve metabolic health and to decrease the risk of mortality \[[@B6-nutrients-09-01223],[@B7-nutrients-09-01223]\]. Regarding cancer risk, coffee consumption has been associated with decreased risk of liver \[[@B8-nutrients-09-01223]\], prostate \[[@B9-nutrients-09-01223]\], pancreatic \[[@B10-nutrients-09-01223]\], and colon cancer \[[@B11-nutrients-09-01223]\], suggesting a potential role of coffee in cancer prevention. Coffee is composed of a variety of compounds, including polyphenols, diterpenes and melanoidins, that have been reported to modulate anti-inflammatory and anti-oxidant body responses, which may explain the potential beneficial effects of coffee in cancer prevention \[[@B12-nutrients-09-01223],[@B13-nutrients-09-01223]\].

A decreased risk of endometrial cancer in women who regularly drink coffee has been documented in retrospective and prospective studies: Je and Giovannucci performed a meta-analysis including 10 case-control and 6 cohort studies and found a significant inverse association of endometrial cancer with coffee consumption in the highest versus the lowest category of coffee intake \[[@B14-nutrients-09-01223]\]. The dose--response analysis showed a decrease of 8% in the risk of endometrial cancer for an increment of one cup of coffee per day \[[@B14-nutrients-09-01223]\]. Similar conclusions were reported by Zhou and colleagues in a meta-analysis of prospective studies: they found a significant reduction of endometrial cancer risk associated with increased coffee consumption, with a linear dose--response relationship \[[@B15-nutrients-09-01223]\]. Significant results were obtained also in the meta-analysis of Yang and colleagues, who estimated a decreased risk of endometrial cancer of about 10% for every additional daily cup of coffee \[[@B16-nutrients-09-01223]\]. Results are promising but evidence is not yet conclusive, especially regarding specific population subgroups (e.g., in relation to body mass index (BMI), age, geographic place of residence, and ethnicity); in light of the high worldwide consumption of coffee, further research is needed \[[@B17-nutrients-09-01223],[@B18-nutrients-09-01223]\]. Moreover, new cohort studies have been published, and some overlapping cohorts were not considered in the previous meta-analyses \[[@B19-nutrients-09-01223]\]. Thus, the aim of this study was to update the current evidence on the association between coffee intake and risk of endometrial cancer, providing insights on potential effect modifiers or confounding factors, including the BMI and the menopausal status.

2. Methods {#sec2-nutrients-09-01223}
==========

We followed the Meta-Analysis of Observational Studies in Epidemiology (MOOSE) protocols throughout the design, execution, analysis, and reporting of the current meta-analysis ([Supplementary Table S1](#app1-nutrients-09-01223){ref-type="app"}) \[[@B20-nutrients-09-01223]\].

2.1. Search Strategy {#sec2dot1-nutrients-09-01223}
--------------------

We conducted a comprehensive literature search using two medical databases, namely, PubMed (<http://www.ncbi.nlm.nih.gov/pubmed/>) and EMBASE (<http://www.embase.com/>); the databases were screened from the earliest available online indexing year up to March 2017, with English-language restriction. We included the following search terms: *(coffee OR caffeine OR beverages OR diet Or dietary) AND (endometrial OR endometrium) AND (cancer OR carcinoma OR neoplasm)* ([Supplementary Table S2](#app1-nutrients-09-01223){ref-type="app"}). Two authors evaluated independently the pertinence of the retrieved studies and obtained full texts of the relevant ones. We limited our search to prospective cohort studies that evaluated the association between dietary coffee intake and the risk of endometrial cancer in the overall female population. Studies were included if they provided any of the following risk estimates: relative risks (RRs) or hazard ratios (HRs). We excluded studies that reported insufficient statistics or insufficient coffee consumption categories (less than three). Among the included manuscripts, all references were also examined in order to maximize the number of relevant studies through the addition of studies not previously identified. When duplicate publications from the same study were identified, we chose the report that provided the largest number of cases (or the entire cohort), or the longest follow-up for each endpoint of interest. Full texts of potentially relevant articles were assessed independently for eligibility by two different authors.

2.2. Data Extraction {#sec2dot2-nutrients-09-01223}
--------------------

A standardized extraction form was used to extract data from each study included in the meta-analysis. The following information was collected: (1) first author name; (2) year of publication; (3) study cohort name; (4) country; (5) number of participants; (6) sex of participants; (7) age range of the study population at baseline; (8) categories of consumption; (9) follow-up period; (10) endpoints and cases; (11) distributions of cases and person-years, RRs, HRs, and 95% CIs (confidence interval) for all categories of exposure; (12) covariates used in adjustments. Two authors independently performed such process, and discrepancies were discussed and resolved by consensus. Each study was critically appraised through the use of a quality scale, namely, the Newcastle-Ottawa Quality Assessment Scale \[[@B21-nutrients-09-01223]\], which consists of three variables of quality as follows: selection (4 points), comparability (2 points), and outcome (3 points), for a total score of 9 points (9 representing the highest quality).

2.3. Statistical Analysis {#sec2dot3-nutrients-09-01223}
-------------------------

In this meta-analysis, HRs were deemed equivalent to relative risks (RRs) \[[@B22-nutrients-09-01223]\]. For each study, extracted statistical estimates were RRs and HRs with 95% CI for all categories of exposure. Random-effects models were used to calculate pooled RRs with 95% CI for the highest versus the lowest categories of exposure (such analysis aimed to assess the presence of a relationship between coffee intake and risk of endometrial cancer). In performing such analysis, for each study, we used the risk estimate derived from the most fully adjusted models (analysis of the pooled RR). Heterogeneity was assessed using the Q test and *I*^2^ statistic. The level of significance was set equal to 0.10 for the Q test. The *I*^2^ statistic explains the amount of total variation that could be attributed to heterogeneity. *I*^2^ values ≤25%, 25--50%, 50--75%, and \>75% indicated no, small, moderate, and significant heterogeneity, respectively. To evaluate the stability of the results and potential sources of heterogeneity, a sensitivity analysis by exclusion of one study at a time was performed. Moreover, a subgroup analysis was performed in order to check for potential sources of heterogeneity according to the geographical area. To test for potential confounders and effect modifiers, other subgroup analyses were performed (by menopausal status, receptor status, BMI, smoking status, and coffee type). The publication bias was evaluated by a visual investigation of the funnel plots for potential asymmetry.

To better explore the relationship between exposure and outcome, a dose--response meta-analysis was performed (a dose--response analysis was preferred over other designs, e.g., meta-regression, to better compare our results with previous studies and to better draft potential recommendations whether evidence would support the present findings). Extracted data were stratified by the level of coffee intake, and distributions of cases and person-years (when available), and RRs or HRs with 95% CIs for ≥3 exposure categories were included. The median or mean intake of coffee in each category was assigned to the corresponding RR or HR with the 95% CI for each study. If coffee consumption was reported in a range of intake, we used the midpoint of the range. Similarly, when the highest category was open-ended, we assumed that the width of the category would be the same as the adjacent category. In the case of an open-ended lowest category, we clearly set the lower boundary to zero. Two-stage random-effects dose--response meta-analysis was performed to examine linear and non-linear relationship between coffee intake and risk of endometrial cancer. In the first stage, the method of Greenland and Longnecker (generalized least-squares, GLS) was used to calculate study-specific coefficients on the basis of results across categories of coffee intake, taking into account the correlation within each set of retrieved RRs and HRs \[[@B23-nutrients-09-01223],[@B24-nutrients-09-01223]\]. Through the use of restricted cubic splines with three knots at fixed percentiles (25%, 50%, and 75%) of the distributions, non-linear dose--response analyses were modelled \[[@B25-nutrients-09-01223]\], and the coefficients (that had been estimated within each study by performing random-effects meta-analysis) were combined. To estimate the relative risks, we used the method of DerSimonian and Laird in linear dose--response meta-analyses, and the multivariate extension of the method of moments in non-linear dose--response meta-analyses. We calculated a *p*-value for non-linearity by testing the coefficient of the second spline as equal to zero. We performed all analyses with R software version 3.0.3 (Development Core Team, Vienna, Austria).

3. Results {#sec3-nutrients-09-01223}
==========

3.1. Study Characteristics {#sec3dot1-nutrients-09-01223}
--------------------------

The search identified 598 studies, of which 511 were excluded after reviewing the title, and 70 on the basis of the abstract ([Figure 1](#nutrients-09-01223-f001){ref-type="fig"}). Of the 17 publications selected, five were excluded for the following reasons: (1) the article did not provide risk measurements with confidence intervals; (2) the article did not have a prospective design; (3) the article provided data only on genetic polymorphism. For the analysis on the association between coffee consumption and endometrial cancer risk, 12 studies were eligible \[[@B16-nutrients-09-01223],[@B26-nutrients-09-01223],[@B27-nutrients-09-01223],[@B28-nutrients-09-01223],[@B29-nutrients-09-01223],[@B30-nutrients-09-01223],[@B31-nutrients-09-01223],[@B32-nutrients-09-01223],[@B33-nutrients-09-01223],[@B34-nutrients-09-01223],[@B35-nutrients-09-01223],[@B36-nutrients-09-01223]\]. Two cohorts, NOWAC and VIP \[[@B27-nutrients-09-01223],[@B33-nutrients-09-01223]\], were excluded from the main analysis because part of theirs cases are included in the multicenter study EPIC \[[@B32-nutrients-09-01223]\]. However, an alternative analysis was performed by including these cohorts and excluding the EPIC study. One article was used only for subgroup analysis \[[@B31-nutrients-09-01223]\]. Studies eligible for the main analysis comprised 1,404,541 participants and 10,548 endometrial cancer cases. The main characteristics of the studies included in the meta-analysis are described in [Table 1](#nutrients-09-01223-t001){ref-type="table"}. Seven studies provided relative risk measurements for the postmenopausal \[[@B26-nutrients-09-01223],[@B27-nutrients-09-01223],[@B28-nutrients-09-01223],[@B29-nutrients-09-01223],[@B30-nutrients-09-01223],[@B31-nutrients-09-01223],[@B35-nutrients-09-01223]\] status, and two for the premenopausal status \[[@B27-nutrients-09-01223],[@B31-nutrients-09-01223]\]. Five studies were conducted in the USA \[[@B28-nutrients-09-01223],[@B29-nutrients-09-01223],[@B30-nutrients-09-01223],[@B31-nutrients-09-01223],[@B35-nutrients-09-01223]\], five in Europe \[[@B16-nutrients-09-01223],[@B26-nutrients-09-01223],[@B27-nutrients-09-01223],[@B33-nutrients-09-01223],[@B36-nutrients-09-01223]\], one in Asia \[[@B34-nutrients-09-01223]\], and one on a cohort from Europe and North America \[[@B32-nutrients-09-01223]\]. The follow-up in prospective cohort studies ranged from about 6 to 26 years, and the age range at study baseline was between 25 and 74 years (with almost all studies covering the age range between 40 and 60 years).

3.2. Summary Relative Risk for Highest vs. Lowest Category of Coffee Consumption {#sec3dot2-nutrients-09-01223}
--------------------------------------------------------------------------------

The summary Relative Risk (RR) of endometrial cancer for the highest versus the lowest category of coffee consumption was RR = 0.79, 95% CI: 0.73, 0.87, with small heterogeneity *I*^2^ = 28%, *p* = 0.19, ([Figure 2](#nutrients-09-01223-f002){ref-type="fig"}); no publication bias was found after a visual inspection of the funnel plot ([Supplementary Figure S1](#app1-nutrients-09-01223){ref-type="app"}). When we performed the alternative analysis that included the NOWAC and VIP cohorts instead of the EPIC study (used in the main analysis), the RR was even lower and equal to 0.73 (95% CI: 0.64, 0.84), with moderate heterogeneity (*I*^2^ = 44%, *p* = 0.0375).

The associations for caffeinated and decaffeinated coffee were consistent with the aforementioned relationship (RR = 0.65, 95% CI: 0.50, 0.85 for caffeinated coffee, and RR = 0.76, 95% CI: 0.62, 0.93 for decaffeinated coffee, [Table 2](#nutrients-09-01223-t002){ref-type="table"}).

When taking into account the menopausal status, a significant decrease in the risk of endometrial cancer (RR = 0.70, 95% CI: 0.63, 0.78; *I*^2^ = 0%, *p* = 0.60) was found for postmenopausal women, but not for premenopausal women (RR = 0.76 95% CI: 0.49, 1.19; *I*^2^ = 16%, *p* = 0.27). No differences were observed between ever-smokers and non-smokers, i.e., in both subgroups the risk was significantly reduced for the highest category of coffee consumption compared to lowest category (RR = 0.78, 95% CI: 0.68, 0.88 for non-smokers, and RR = 0.74, 95% CI: 0.57, 0.98 for ever-smokers, respectively, [Table 2](#nutrients-09-01223-t002){ref-type="table"}). Finally, the analysis of the highest versus the lowest category of coffee consumption according to body mass index (BMI) categories showed a significant decrease in the risk of endometrial cancer among the obese (BMI \> 30 kg/m^2^) women (RR = 0.75, 95% CI: 0.63, 0.88).

3.3. Dose--Response Meta-Analysis {#sec3dot3-nutrients-09-01223}
---------------------------------

Nine studies \[[@B16-nutrients-09-01223],[@B26-nutrients-09-01223],[@B28-nutrients-09-01223],[@B29-nutrients-09-01223],[@B30-nutrients-09-01223],[@B32-nutrients-09-01223],[@B34-nutrients-09-01223],[@B35-nutrients-09-01223],[@B36-nutrients-09-01223]\] were eligible for dose--response meta-analysis of prospective cohort studies on coffee consumption and endometrial cancer risk. Six studies \[[@B26-nutrients-09-01223],[@B27-nutrients-09-01223],[@B28-nutrients-09-01223],[@B29-nutrients-09-01223],[@B30-nutrients-09-01223],[@B31-nutrients-09-01223]\] provided risk estimates for postmenopausal women only. In both the non-linear and the linear dose--response meta-analyses, a significant association between coffee consumption and endometrial cancer risk was found ([Figure 3](#nutrients-09-01223-f003){ref-type="fig"}, [Table 3](#nutrients-09-01223-t003){ref-type="table"}). Compared to no coffee consumption, the pooled relative risks for endometrial cancer were: 0.95, 95% CI: 0.92, 0.97, for one cup/day; 0.90, 95% CI: 0.85, 0.94, for two cups/day; 0.85, 95% CI: 0.78, 0.92, for three cups/day; 0.80, 95% CI: 0.72, 0.89, for four cups/day; 0.76, 95% CI: 0.67, 0.86, for five cups/day; 0.72, 95% CI: 0.61, 0.84, for six cups/day; 0.68, 95% CI: 0.57, 0.81, for seven cups/day. Two cohorts, NOWAC and VIP, were excluded from the main analysis, as part of theirs cases are included in the multicentre study EPIC. However, an alternative analysis was performed by including these cohorts and excluding the EPIC study, confirming the results of the main analysis ([Supplementary Table S3](#app1-nutrients-09-01223){ref-type="app"}). Finally, the association between coffee intake and endometrial cancer was stronger when taking into consideration postmenopausal women.

4. Discussion {#sec4-nutrients-09-01223}
=============

The present meta-analysis, including 12 prospective cohort studies, showed that coffee consumption is associated with a lower risk of endometrial cancer; such association was stronger for postmenopausal endometrial cancer and in obese women (BMI \> 30).

Various meta-analyses on the association of coffee consumption and endometrial cancer risk have been conducted so far: for instance, in 2011 Je and Giovannucci \[[@B14-nutrients-09-01223]\] documented an inverse dose--response association, with a geographical gradient (stronger association in Japan, followed by the USA and then Europe). Subgroup analyses were later published in 2015 by Yang and colleagues \[[@B16-nutrients-09-01223]\] and by Zhou and colleagues \[[@B15-nutrients-09-01223]\]: both groups limited their analyses to prospective studies and found a linear inverse association. The first research group found some evidence of heterogeneity among BMI subgroups (overweight women, with a BMI higher than 25, showed a more pronounced inverse association than women with a lower BMI). The second group confirmed these results and pointed out a similar pattern for women without a history of hormone therapy, while documenting no differences with respect to study location, smoking status, and menopausal status. Compared to the previous literature, our results, especially on subgroup analyses for postmenopausal status and BMI (overweight vs obese), are in line with the reported observations, yet provide original findings.

Coffee constituents have been associated with several biological mechanisms related to carcinogenesis, both in vitro and in vivo. These mechanisms include: DNA methylation, oxidative damage, activation of proto-oncogenes and inactivation of onco-suppressor genes, loss of apoptosis and growth control, and induction of angiogenesis \[[@B37-nutrients-09-01223],[@B38-nutrients-09-01223]\]. Active coffee constituents that have been identified include not only caffeine (mainly known for its ability to increase blood pressure and for its psychostimulatory and diuretic properties) \[[@B39-nutrients-09-01223]\], but also polyphenols (e.g., chlorogenic acids, which produce catechins, caffeic, ferulic and coumaric acids), lipids in the form of diterpenes (e.g., cafestol and kahweol), melanoidins, and trigonelline \[[@B40-nutrients-09-01223],[@B41-nutrients-09-01223]\]. There is evidence that dietary polyphenols might be associated with decreased mortality and cancer risk, and may be the mediators of the potential effects of coffee on cancer prevention \[[@B42-nutrients-09-01223],[@B43-nutrients-09-01223]\].

With particular referral to female reproductive cancers, several mechanisms have been proposed: for instance, caffeine and coffee intake have been positively associated to sex hormone-binding globulin (SHBG) in postmenopausal women \[[@B44-nutrients-09-01223]\]. SHBG is the major carrier of estrogens and testosterone, thus lowering the circulating levels of free hormones; the positive relationship between coffee or caffeine intake and SHBG has been proved in many studies \[[@B45-nutrients-09-01223],[@B46-nutrients-09-01223]\]. Another possible mechanism resulting in lower levels of circulating estrogens after coffee intake is through the inhibition of the enzyme converting androgens into estrogens, i.e., CYP19 or aromatase \[[@B44-nutrients-09-01223]\]. A low level of estrogens is considered a protective factor against endometrial cancers acting through the down-regulation of endometrial proliferation \[[@B45-nutrients-09-01223]\], and the inverse association between coffee or caffeine consumption and estrogens has been widely documented \[[@B47-nutrients-09-01223],[@B48-nutrients-09-01223]\].

Additional effects of coffee and caffeine intake on hormonal functions have been seen in improved insulin sensitivity as a result of the stimulation of insulin-mediated uptake of glucose \[[@B49-nutrients-09-01223]\]. Coffee could therefore have a protective role against type 2 diabetes development: most epidemiological studies have documented an inverse association between the intake of caffeinated coffee, decaffeinated coffee, and caffeine and type 2 diabetes in a dose--response manner compared with no or infrequent coffee consumption \[[@B50-nutrients-09-01223]\]. In turn, type 2 diabetes has been associated with an increased risk of endometrial cancer, and more specifically with an increased risk of type 1 endometrioid endometrial adenocarcinoma \[[@B51-nutrients-09-01223]\]. In recent epidemiological studies, such risk has been associated not only with insulin resistance and diabetes, but also with the metabolic syndrome that is characterized by the coexistence of various factors, such as abdominal obesity, low levels of high density lipoprotein, elevated levels of triglycerides and low levels of density lipoprotein, hypertension, and insulin resistance \[[@B52-nutrients-09-01223],[@B53-nutrients-09-01223]\].

As already pointed out, we observed a stronger association between coffee consumption and endometrial cancer in women with high BMI (above 30) compared with women with a BMI of 25 or lower. Overweight and obesity have been associated with the development of cancers \[[@B54-nutrients-09-01223]\], and various mechanisms have been proposed, including: (i) chronic inflammation and oxidative stress; (ii) cross-talk between tumor cells and surrounding adipocytes; (iii) migration of adipose stromal cells; (iv) obesity-induced hypoxia; (v) genetic susceptibility; and (vi) immunological dysfunctions \[[@B55-nutrients-09-01223]\]. In several studies, coffee intake has been inversely associated with metabolic syndrome \[[@B56-nutrients-09-01223],[@B57-nutrients-09-01223],[@B58-nutrients-09-01223],[@B59-nutrients-09-01223],[@B60-nutrients-09-01223],[@B61-nutrients-09-01223],[@B62-nutrients-09-01223],[@B63-nutrients-09-01223],[@B64-nutrients-09-01223],[@B65-nutrients-09-01223],[@B66-nutrients-09-01223]\]. Metabolic risk factors, such as obesity, impaired glucose tolerance, dyslipidemia, and hypertension have been linked to elevated systemic inflammation and oxidative stress. Thus, impaired metabolism may induce inflammation and oxidative stress, which in turn may lead to carcinogenic transformation. Within these pathways, four main components have been identified: insulin, insulin-like growth factor-I, sex steroids, and adipokines, and coffee consumption has been associated, directly or indirectly, with most of them \[[@B55-nutrients-09-01223]\]. For instance, an in vitro study showed that exposure to coffee reduced the accumulation of lipids inhibiting adipocytic differentiation \[[@B67-nutrients-09-01223]\]. In animal models, coffee consumption has been related to changes in transcription factors and lipogenesis-related proteins, and, in epidemiological studies, decreased body weight and decreased visceral fat, in relation to coffee consumption, have been observed \[[@B68-nutrients-09-01223]\].

The present meta-analysis has some limitations. First, despite we provided insights on underrated factors potentially affecting the association between coffee consumption and endometrial cancer risk, other variables (such as the type of coffee seeds, the roasting method, and the type of preparation) remained largely unexplored. Second, we cannot rule out the possibility of changes in dietary habits (i.e., increased or decreased consumption of coffee) over time, leading to the risk of reverse causation in the event that an individual changed coffee intake due to a newly diagnosed medical condition.

5. Conclusions {#sec5-nutrients-09-01223}
==============

In conclusions, our findings suggest that increased coffee consumption is associated with decreased risk of endometrial cancer, especially in postmenopausal, obese women.
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![Selection process of relevant studies reporting on the association between coffee consumption and endometrial cancer risk.](nutrients-09-01223-g001){#nutrients-09-01223-f001}

![Forest plot of summary relative risks (RRs) of endometrial cancer for the highest versus the lowest (reference) category of coffee consumption. Exposure categories are reported as identified in the original studies; in the dose--response analysis they were harmonized (range: 0--9 cups).](nutrients-09-01223-g002){#nutrients-09-01223-f002}

![Dose--response association between coffee consumption and endometrial cancer risk (**a**) non-linear, total analysis; (**b**) linear, total analysis (**c**) non-linear, postmenopausal; (**d**) linear, postmenopausal.](nutrients-09-01223-g003){#nutrients-09-01223-f003}

nutrients-09-01223-t001_Table 1

###### 

Characteristics of the studies included in the meta-analysis.

  Author, Year       Cohort Name, Country               Years of Study, Follow-Up                                                                           Cases; Total Population                       Age Range                                                 Adjustments
  ------------------ ---------------------------------- --------------------------------------------------------------------------------------------------- --------------------------------------------- --------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Shimazu, 2008      JPHC, Japan                        1990--2005, 15 years (maximum)                                                                      117; 53,724                                   40--59 years                                              Age, study area, BMI (body mass index), menopausal status, age at menopause for postmenopausal women, parity, use of exogenous female hormones, smoking status, green vegetable consumption, beef consumption, pork consumption, and green tea consumption.
  Friberg, 2009      SMC, Sweden                        1992--2007, 17.6 years (mean)                                                                       677; 60,634                                   40--76 years                                              Age, BMI, smoking.
  Nilsson, 2010      VIP, Sweden                        1985--2007, 6 years (median)                                                                        108; 32,178                                   30--60 years                                              Age, sex, BMI, smoking, education, recreational physical activity.
  Giri, 2011         WHI, USA                           1993--2005, 7.5 years (average)                                                                     427; 45,696                                   50--79 years                                              Age, ethnicity, unopposed estrogen use, progestin + estrogen use, smoking, BMI.
  Je, 2011           NHS, USA                           1980--2006, 26 years (maximum)                                                                      672; 67,470                                   34--59 years                                              Age, BMI, age at menopause, age at menarche, parity and age at last birth, duration of oral contraceptive use, postmenopausal hormone use, pack-years of smoking, alcohol intake, and total energy intake, tea analysis.
  Gunter, 2011       NIH-AARP, USA                      1995--2006, 9.3 years (mean)                                                                        1486; 111,429                                 50--71 years                                              Age, smoking, BMI, age at menarche, age at first child's birth, parity, age at menopause, HT (hormonal therapy) use, oral contraceptive use, diabetes and physical activity.
  Ucella, 2013       IWHS, USA                          1986--2005, 20 years (maximum)                                                                      542; 23,356                                   55--69 years                                              Age, diabetes, duration of HT use, hypertension, age at menarche, age at menopause, BMI, waist-to-hip ratio, smoking status, pack years of smoking, total energy and alcohol use.
  Gavrilyuk, 2011    NOWAC, Norway                      1991--2007, 10.9 (average)                                                                          462; 97,926                                   30--70 years                                              Parity, smoking status, BMI, duration of OC (oral contracception) and HRT use.
  Weiderpass, 2014   WLH, Sweden                        1991--2009, 18 years (maximum)                                                                      144; 42,270                                   30-49 years                                               Age, education, duration of hormonal contraceptive use, parity, duration of breastfeeding, smoking status and number of cigarettes/day, menopausal status, BMI, and diabetes mellitus.
  Merritt, 2015      EPIC, Multicentre; NHS/NHSII USA   EPIC 1992-NA, 11 years (mean); NHS 1976--2010, 25 years (mean); NHSII 1989--2011, 25 years (mean)   EPIC 1303; 301,107; NHS/NHSII 1531; 155,406   EPIC 25--70 years; NHS 30--55 years; NHSII 25--42 years   BMI, total energy intake, smoking status, age at menarche, oral contraceptive use, a combined variable for menopausal status and postmenopausal hormone (PMH) use, parity, and was stratified by the age of recruitment, and the study centre.
  Owen Yang, 2015    MWS, UK                            1996--2001, 9.3 years (average)                                                                     4067; 560,356                                 \~60 years (mean)                                         Age, region, socioeconomic status, height, age at menarche, parity, duration of oral contraceptive use, age and status of menopause at study baseline, duration of hormone therapy for menopause, BMI, smoking, alcohol consumption, strenuous exercise, tea consumption, and other nonalcohol fluid intake.
  Hashibe, 2015      PLCO, USA                          1992--2011, 13 years (maximum)                                                                      254; 50,563                                   55--74 years                                              Age, sex, race, education, smoking status, smoking frequency, smoking duration, time since stopping smoking for past smokers, and drinking frequency.

Abbreviations: EPIC ([*European Prospective Investigation into Cancer and Nutrition*]{.ul}); IWHS (Iowa Women's Health Study); JPHC (Japan Public Health Center-based Prospective Study); NHS (The Nurses' Health Study); MWS (Million Women Study); NIH-AARP (NIH-AARP Diet and Health Study); NOWAC (The Norwegian Women and Cancer study); PLCO ([*Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial*]{.ul}); SMC ([*The Swedish Mammography Cohort*]{.ul}); WHI (Women's Health Initiative); WLH (Women's Lifestyle and Health); VIP (Västerbotten intervention project cohort).

nutrients-09-01223-t002_Table 2

###### 

Subgroups and additional analyses of studies reporting the risk of endometrial cancer for the highest versus the lowest (reference) category of coffee consumption (analyses based on 12 studies consisting of 10 databases).

  Subgroup/Additional Analysis   No. of Datasets   RR (95% CI)         *I*^2^   *P~heterogeneity~*
  ------------------------------ ----------------- ------------------- -------- --------------------
  Total                          10                0.79 (0.73, 0.87)   28%      0.19
  Geographical area                                                             
  North America                  5                 0.75 (0.67, 0.84)   6%       0.37
  Europe                         4                 0.84 (0.74, 0.94)   29%      0.24
  Asia                           1                 0.97 (0.56, 1.68)   NA       NA
  Menopausal status                                                             
  Postmenopausal                 7                 0.70 (0.63, 0.78)   0%       0.60
  Premenopausal                  2                 0.76 (0.49, 1.19)   16%      0.27
  Coffee type                                                                   
  Caffeinated                    4                 0.65 (0.50, 0.85)   64%      0.04
  Decaffeinated                  4                 0.76 (0.62, 0.93)   0%       0.72
  BMI                                                                           
  \<25 kg/m^2^                   7                 0.99 (0.86, 1.14)   0%       0.58
  \>25 kg/m^2^                   7                 0.79 (0.61, 1.01)   66%      0.004
  \>30 kg/m^2^                   5                 0.75 (0.63, 0.88)   22%      0.27
  Smoking status                                                                
  Never smoker                   8                 0.78 (0.68, 0.88)   7%       0.38
  Ever smoker (former/current)   8                 0.74 (0.57, 0.98)   68%      0.003
  Adjusted for smoking                                                          
  No                             0                 NA                  NA       NA
  Yes                            10                0.79 (0.73, 0.87)   28%      0.19
  Adjusted for BMI                                                              
  No                             1                 0.69 (0.52, 0.91)   NA       NA
  Yes                            9                 0.80 (0.74, 0.88)   27%      0.20
  Adjusted for education                                                        
  No                             8                 0.81 (0.74, 0.89)   30%      0.19
  Yes                            2                 0.68 (0.53, 0.87)   0%       0.80
  Adjusted for alcohol intake                                                   
  No                             8                 0.77 (0.71, 0.84)   0%       0.56
  Yes                            2                 0.85 (0.67, 1.07)   52%      0.15

nutrients-09-01223-t003_Table 3

###### 

Dose--response meta-analysis of prospective cohort studies on coffee consumption and endometrial cancer risk.

                   No. of Datasets (No. of Studies)   Coffee Intake (Cups/Day)   *I*^2^*(%)*         *P~heterogeneity~*   *P~non-linearity~*                                                                                                  
  ---------------- ---------------------------------- -------------------------- ------------------- -------------------- -------------------- ------------------- ------------------- ------------------- ------------------- ------- ------ ------
  Total analysis                                                                                                                                                                                                                              
  Non-linear       11 (9)                             Ref.                       0.91 (0.85, 0.97)   0.85 (0.76, 0.94)    0.81 (0.73, 0.91)    0.79 (0.70, 0.89)   0.76 (0.67, 0.87)   0.74 (0.64, 0.86)   0.72 (0.61, 0.85)   30.98   0.09   0.09
  Linear           11 (9)                             Ref.                       0.95 (0.92, 0.97)   0.90 (0.85, 0.94)    0.85 (0.78, 0.92)    0.80 (0.72, 0.89)   0.76 (0.67, 0.86)   0.72 (0.61, 0.84)   0.68 (0.57, 0.81)   59.21   0.01   NA
  Postmenopausal                                                                                                                                                                                                                              
  Non-linear       7 (6)                              Ref.                       0.92 (0.83, 1.01)   0.85 (0.73, 0.99)    0.80 (0.69, 0.92)    0.75 (0.65, 0.87)   0.71 (0.61, 0.83)   0.67 (0.56, 0.79)   0.63 (0.52, 0.76)   0       0.64   0.67
  Linear           7 (6)                              Ref.                       0.93 (0.91, 0.95)   0.87 (0.83, 0.91)    0.81 (0.76, 0.87)    0.76 (0.69, 0.83)   0.71 (0.63, 0.79)   0.66 (0.58, 0.76)   0.62 (0.53, 0.72)   0       0.46   NA
